Premium
Treatment selection for first‐line metastatic renal cell carcinoma in Australia: Impact of new therapy options
Author(s) -
Schmidt Andrew,
Azad Arun,
Goh Jeffrey,
Harris Carole,
Joshua Anthony M.,
Weickhardt Andrew,
Krieger Laurence
Publication year - 2019
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13289
Subject(s) - renal cell carcinoma , medicine , oncology , selection (genetic algorithm) , targeted therapy , clear cell renal cell carcinoma , intensive care medicine , cancer , artificial intelligence , computer science
Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno‐oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.